spacer
home > pmps > autumn 2018 > managing medication
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Managing Medication

Medication nonadherence is a serious public health issue. It costs the NHS approximately £500 million every year, as well as countless hours of work dealing with problems which arise due to patients not taking prescribed medications as directed. As the former US general surgeon, Dr C Everett Koop, stated, “drugs don’t work in patients who don’t take them.”

Across the UK, one billion items are prescribed and dispensed by pharmacists every year. However, one in five patients surveyed as part of the True Cost of Medication Non- Adherence report admitted to not taking their medication as prescribed. “Non-adherence is a big problem,” Ric Fordham, Professor of Applied Health and Economics at the University of East Anglia, UK, said in the study. “When patients don’t feel ill, or they start to feel better, they think there is no need for them to take their drugs anymore. Patients then don’t get the full benefit of them and that ends up reducing the cost effectiveness of the drugs.”

Nonadherence can be classified as intentional (when a patient actively decides not to take medication or follow treatment recommendations) or unintentional (which can be caused by misunderstanding the prescription requirements, an inability to access or administer prescribed medication, or simple forgetfulness). The National Institute for Health and Care Excellence states that nonadherence should not be considered as just the patient’s problem; ultimately, it represents a fundamental limitation in the delivery of healthcare.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Oliver Pittock is the Managing Director of pharmaceutical packaging specialist, Valley Northern. Oliver built his commitment to the healthcare and pharmacy supply business through seeing his father’s business grow throughout the 1970s. Moving to the Midlands in 1993, Oliver set up Valley Northern, which became a limited company in 2014.
spacer
Oliver Pittock
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Envigo launches PATHWAY an optimized safety assessment solution to enable first in human clinical trials

11 March 2019, East Millstone, N.J. – Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials. PATHWAY is designed to manage the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers by integrating safety assessment study types and bioanalytical support with scientific and regulatory consulting, program design and project management.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement